Life Biosciences Doses 1st Patient With ER-100 for Glaucoma as Aging-Reversal Gene Therapy Enters Human Testing
Updated
Updated · Gizmodo · Jun 9
Life Biosciences Doses 1st Patient With ER-100 for Glaucoma as Aging-Reversal Gene Therapy Enters Human Testing
3 articles · Updated · Gizmodo · Jun 9
Summary
Four months after FDA clearance, Life Biosciences said it has treated its first glaucoma patient with ER-100, an experimental gene therapy aimed at regenerating optic-nerve neurons by reversing age-related epigenetic changes.
ER-100 delivers tailor-made genes by modified virus and is designed to switch on only when patients take doxycycline, with the company planning roughly 8 weeks of continuous activation to balance reprogramming and safety.
The approach builds on David Sinclair lab work showing three genes restored vision in aging and glaucoma mice, and Life says it has further refined the therapy in nonhuman primate studies.
Cancer risk remains the central concern: researchers warn Yamanaka-factor reprogramming can trigger uncontrolled growth, and earlier experiments in the field have produced teratomas in animals.
The trial marks an early test of longevity medicine in humans, though backers say any broader anti-aging use remains distant despite Sinclair's separate push for an oral rejuvenation drug and a $101 million XPrize.
If this eye injection proves aging can be reversed, are we ready for a world without natural lifespans?
Scientists are reprogramming human cells to be young again. What stops this from accidentally triggering cancer?
As billionaires fund the quest to reverse aging, will eternal youth become a luxury only the wealthy can afford?
First-in-Human Trial of ER-100: Pioneering Epigenetic Rejuvenation Therapy Targets Age-Related Vision Loss
Overview
Life Biosciences has made a major step in regenerative medicine by dosing the first human in a Phase 1 clinical trial of ER-100, an investigational gene therapy for age-related vision loss. ER-100 targets conditions like open-angle glaucoma and NAION, using the company’s Epigenetic Restoration platform. This platform works by controlling the expression of three key transcription factors—OCT4, SOX2, and KLF4—to rejuvenate damaged cells. The trial, which began in early 2026, aims to test if this innovative approach can safely restore vision by reversing cellular aging, marking a new era in treating age-related diseases.